1 / 5

Reviewer: Dr. Charles Butts Date posted: June 21, 2007

A randomized, double-blind phase III study of Bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advancedor recurrent non-squamous NSCL cancer (AVAiL). Authors: Manegold et al. Reviewer: Dr. Charles Butts Date posted: June 21, 2007. Treatment A:

dewitt
Download Presentation

Reviewer: Dr. Charles Butts Date posted: June 21, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A randomized, double-blind phase III study of Bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advancedor recurrent non-squamous NSCL cancer (AVAiL).Authors: Manegold et al. Reviewer: Dr. Charles Butts Date posted: June 21, 2007

  2. Treatment A: Cisplatin 80 mg/m2 Day 1/Gem 1250 mg/m2 Day 1,8 + Placebo R Treatment B: Cisplatin/Gem + Bevacizumab 7.5 mg/m2 weekly or 15 mg/m2 weekly Advanced or recurrent Non-squamous ECOG 0-1

  3. RESULTS

  4. STUDY COMMENTARY • This randomized trial of chemo +/- bevacizumab at 2 doses was designed to confirm the benefit seen in the ECOG 4599 trial. • It included the same study population and had similar exclusion criteria as ECOG 4599. The major difference was the use of cisplatin/gemcitabine versus carboplatin/paclitaxel and the testing of the 7.5 mg/m2 bevac dose versus the 15 mg/m2 dose used in the ECOG trial. • In this trial (AVAiL) there was less toxicity concern with the addition of bevacizumab. • There did not appear to be an additional benefit from 15 mg/m2 of bevac versus 7.5 mg/m2 ( although the trial was not designed for a formal comparison of these arms) • Although the primary end point of improvement in PFS was met, the absolute difference seen with the addition of Bevac was .6 months (18 days).

  5. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • This trial does confirm the results of the ECOG trial in that a statistically significant improvement in response and PFS were seen. • However, the magnitude of the PFS benefit seen with bevac is very small and of questionable clinical significance. • I doubt that these results will have cancer agencies rushing to fund bevacizumab in the NSCL cancer setting.

More Related